Literature DB >> 11593431

MTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent protein kinase in lymphocytes.

T Fukuyama1, E Sueoka, Y Sugio, T Otsuka, Y Niho, K Akagi, T Kozu.   

Abstract

AML1-MTG8 chimeric oncogene is generated in acute myelogenous leukemia with t(8;21), and seems to be responsible for the pathogenesis of the disease. However, the role of MTG8 is ambiguous. Here we found that MTG8 interacted with the regulatory subunit of type II cyclic AMP-dependent protein kinase (PKA RIIalpha). The binding site of MTG8 was NHR3 domain, and that of RIIalpha was the N-terminus for interacting with PKA anchoring proteins (AKAPs). NHR3 contains a putative alpha-amphipathic helix which is characteristic in binding of AKAPs with RII. Indirect immunofluorescence microscopy showed that MTG8 and RIIalpha were overlapped at the centrosome-Golgi area in lymphocytes. These findings suggest that MTG8 may function as an AKAP at the centrosome-Golgi area in lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593431     DOI: 10.1038/sj.onc.1204794

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  The identification of novel cyclic AMP-dependent protein kinase anchoring proteins using bioinformatic filters and peptide arrays.

Authors:  William A McLaughlin; Tingjun Hou; Susan S Taylor; Wei Wang
Journal:  Protein Eng Des Sel       Date:  2010-11-29       Impact factor: 1.650

2.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

3.  Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.

Authors:  Sangho Park; Wei Chen; Tomasz Cierpicki; Marco Tonelli; Xiongwei Cai; Nancy A Speck; John H Bushweller
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

4.  Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.

Authors:  Yizhou Liu; Wei Chen; Justin Gaudet; Matthew D Cheney; Liya Roudaia; Tomasz Cierpicki; Rachel C Klet; Kari Hartman; Thomas M Laue; Nancy A Speck; John H Bushweller
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

5.  Regulating small G protein signaling to coordinate axon adhesion and repulsion.

Authors:  Taehong Yang; Jonathan R Terman
Journal:  Small GTPases       Date:  2012-12-17

6.  14-3-3ε couples protein kinase A to semaphorin signaling and silences plexin RasGAP-mediated axonal repulsion.

Authors:  Taehong Yang; Jonathan R Terman
Journal:  Neuron       Date:  2012-04-12       Impact factor: 17.173

7.  Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.

Authors:  Takeshi Corpora; Liya Roudaia; Zaw Min Oo; Wei Chen; Ekaterina Manuylova; Xiongwei Cai; Michael J Chen; Tomasz Cierpicki; Nancy A Speck; John H Bushweller
Journal:  J Mol Biol       Date:  2010-08-11       Impact factor: 5.469

8.  Mtg16/Eto2 contributes to murine T-cell development.

Authors:  Aubrey Hunt; Melissa Fischer; Michael E Engel; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

9.  CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

Authors:  Liya Roudaia; Matthew D Cheney; Ekaterina Manuylova; Wei Chen; Michelle Morrow; Sangho Park; Chung-Tsai Lee; Prabhjot Kaur; Owen Williams; John H Bushweller; Nancy A Speck
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

10.  MyRIP anchors protein kinase A to the exocyst complex.

Authors:  April S Goehring; Benjamin S Pedroja; Simon A Hinke; Lorene K Langeberg; John D Scott
Journal:  J Biol Chem       Date:  2007-09-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.